ORLANDO, Fla. and DUBLIN, Jan. 23,
2015 /PRNewswire/ -- Immune Therapeutics, Inc. (OTC-BB:
IMUN) today announced the signing of the agreement with KRS Global
Biotechnology, Inc. for the compounding, packaging and distributing
of its naltrexone tablets. The tablets will be compounded for
shipment in the United States.
KRS Global is a 503B FDA approved Outsourcing Facility capable
of compounding naltrexone tablets in various strengths for
individual patients in response to a prescription from a licensed
physician.
Immune Therapeutics has exclusive proprietary and legal rights
licenses and patents for Low Dose Naltrexone for the following
indications: Crohn's Disease, IBS and inflammatory diseases,
prostate cancer, lymph proliferative syndrome, including such
diseases as malignant lymphoma, chronic lymphocytic leukemia,
Hodgkin's lymphoma, and non-Hodgkin's lymphoma, infectious diseases
such as chronic herpes virus infections, including chronic genital
herpes caused by the herpes simplex virus, Type 2, Fibromyalgia,
Parkinson, chronic infections due to the Epstein-Barr virus, and
chronic inflammatory conditions including chronic fatigue syndrome,
a treatment method for humans infected with HTLV-III (AIDS) virus,
including patients clinically diagnosed as suffering from AIDS, and
those suffering from AIDS-related complex (ARC).
Seth Elliott, President and Chief
Operating Officer of Immune Therapeutics, stated, "This agreement
with KRS Global will help people looking to purchase a formulated
product while protecting Immune Therapeutics' intellectual
property. We expect that the payments to Immune Therapeutics
under the agreement with KRS Global will allow the company to
provide funds to Cytocom Inc. so they can complete clinical trials
with the FDA for Low Dose Naltrexone in Crohn's Disease, MS,
HIV/AIDS, in addition to other indications."
KRS Global is a recognized leader in pharmaceutical compounding,
helping Physicians and Veterinarians with medicine precisely
customized for each individual patient. Very few compounding
pharmacies in the nation have implemented the quality control
standards performed at its facility. Their on-site testing,
sterilization and formulations allow KRS Global to provide patients
with exactly what they expect to receive from their hospital; a
compounded preparation that can be trusted. For more information
about KRS Global visit www.GBTBIO.com.
The information contained herein is general in nature and is
intended for use only as an informational aid. It does not cover
all possible uses, actions, precautions, side effects, or
interactions of Low Dose Naltrexone, nor is the information
intended as medical advice or diagnosis for individual health
problems.
Low Dose Naltrexone has not been evaluated by the Food and Drug
Administration (FDA) and is not made under the FDA's GMP
requirements. It is compounded in a licensed compounding pharmacy.
The compound is for the use of an individual patient who has been
prescribed Low Dose Naltrexone by a licensed physician. The
information contained herein is not intended for making an
evaluation as to suitability, risks or benefits. Before taking any
action, consult your Physician.
About Immune Therapeutics, Inc.
We are a biotechnology company working to combat chronic,
life-threatening diseases through the activation and modulation of
the body's immune system using our patented immunotherapy. Our
products and immunotherapy technologies are designed to harness the
power of the immune system to improve the treatment of cancer,
infections such as HIV/AIDS, chronic inflammatory diseases, and
autoimmune diseases.
Our proprietary technology, therapies and patents include the
treatment of a wide range of cancers. Our most advanced clinical
programs involve immunotherapy with met-enkephalin (MENK)
(sometimes referred to as opioid growth factor) and our Low Dose
Naltrexone product (LDN) or Lodonal™, which have been shown to
stimulate the immune system even in patients with advanced
cancer.
Even though management considers any condition that results in
altered-immune response a target for investigation, we will most
likely pursue additional investigations for MENK and LDN as
valuable candidates in the treatment of autoimmune states such as
rheumatoid arthritis and multiple sclerosis; as an adjunct in
cancer patients undergoing chemotherapy, radiation treatments or
surgery; and as a complement to antibiotics in the treatment of a
variety of infectious diseases, including patients with HIV/AIDS,
in combination with retroviral drug therapy.
About Cytocom Inc.
Cytocom Inc. is a biotechnology company that will initially
focus on developing LDN (Lodonal™) and MENK in the investigation of
unmet medical needs in the areas of oncological and inflammatory
diseases.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This announcement contains statements, which constitute
"forward-looking statements." Forward-looking statements
include any statements related to the agreement with KRS Global,
and are generally identified by words such as "believe," "expect,"
"anticipate," "intend," "estimate," "will," "may," "continue,"
"should" and other similar expressions. Forward-looking statements
are subject to various risks and uncertainties, many of which are
difficult to predict and generally beyond the control of Immune
Therapeutics, that could cause actual results and developments to
differ materially from those expressed in, or implied or projected
by, the forward-looking statements. As a result, recipients should
not rely on such forward-looking statements. Subject to compliance
with applicable law and regulations, Immune Therapeutics does not
intend to update these forward-looking statements and does not
undertake any obligation to do so.
Contact: Dennis S. Dobson
President and CEO
Dobson Media Group and
International Investor Relations Services Inc.
203-258-0159
www.dobsonmediagroup.com
SOURCE Immune Therapeutics, Inc.